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Vaccines’ designThe increasing resistance of many microbial strains to antibiotics, delayed laboratory results, and side
effects of many chemotherapeutics has raised the need to search for sensitive diagnostics and new pro-
phylactic strategies especially prevention by vaccination. Understanding the epitope/antibody interac-
tion is the key to constructing potent vaccines and effective diagnostics. B-cell epitope mapping is a
promising approach to identifying the main antigenic determinants of microorganisms, in special con-
cern the discontinuous conformational ones. Epitope-based vaccines have remarkable privilege over
the conventional ones since they are specific, able to avoid undesirable immune responses, generate long
lasting immunity, and are reasonably cheaper. This up-to-date review discusses and compares the differ-
ent physical, computational, and molecular methods that have been used in epitope mapping. The role of
each method in the identification of potent epitopes in viruses, bacteria, fungi, parasites, as well as
human diseases are tagged and documented. Simultaneously, frequent combinatorial methods are high-
lighted. The article aims to assist researchers to design the most suitable protocol for mapping their B-cell
epitopes.
 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Immunology has a great impact on improving global health
through the synthesis of rapid diagnostics. Simultaneously, it
paved the road towards the protection, as well as the complete
eradication, of many pathogens via the art of vaccination [1,2].
Antibodies (Abs), also known as immunoglobulins (Igs) are essen-
tial components of the immune system of all vertebrates. They are
able to identify and neutralize foreign immuno-stimulating objects
such as viruses, bacteria, parasites, fungi, cancer cells, and some
toxins by binding to specific parts on their surface, that are usually
called antigens (Ag) [3]. In fact, the paratope, a specific part of an
antibody, binds to a particular region on the antigen that is called
the epitope or the antigenic determinant [3,4]. Unlike the T-cell
epitopes, the majority of the functional B-cell epitopes are discon-
tinuous non-linear epitopes having 3D-conformational structures
[5]. The studies of paratope–epitope interaction are considered
recent [6]. Their study offers benefits to the fields of research in
immune response, vaccines and diagnostics design, passive immu-
nization, allergens, and auto-immunity [7,8].
The production of diagnostics and immunotherapeutics first
depended on the use of the whole antigen upon trial and error
methods or virulence studies guidance [2,9]. However, the degree
of success of any epitope depends on its ability to induce the most
specific and detectable rapid immune response in the case of diag-
nostics. While it lies on its capability to confer a neutralizing safe
response for vaccines (B-cell dependent response) [10]. Moreover,
its ability to stimulate cytotoxic or long-lasting potent immune
response (T-cell dependent response) for vaccine production as
well [11]. Therefore, epitope mapping has developed in order to
focus on the selection of the most potent epitopes that could serve
as potential targets for the production of epitope-based diagnostics
and vaccines [1,4,12]. A special concern is dedicated for DNA vac-
cines that are built upon short peptide chains [13]. It was noticed
that the presentation of non-protective epitopes deviates the
immune system potency [1,14,15], and decreases the antigen–an-
tibody affinity [16]. Therefore, epitope-based vaccines aim to pro-
vide protective focused immunity without mimicking the host self-
antigens, which render them safe regarding autoimmune disease
induction [1,14,15]. Vaccines’ mapping aid in reducing the cost,
complexity, and time of synthesis [1].
Although B-cell epitope mapping is the corner stone-step in the
production of diagnostics, it is only the first step to design potent
vaccines [1,10,12,17]. Epitope mapping will not lead to the straight
forward identification of highly protective monoclonal antibodies
(mAbs), as some antibodies that showed neutralizing activity
in vitro were not able to do so in vivo. Moreover, they can give rise
to in vivo antibody dependent enhancement (ADE), a phenomenon
that increases the infectivity of host cells to viruses in the presence
of some antiviral antibodies [18]. In addition to this, several epi-
tope mapping techniques cannot differentiate between conforma-
tional and linear epitopes. Thus, careful considerations have to be
taken when analyzing the results acquired by different methods
used in mapping [1,4,19]. Furthermore, results obtained could be
enhanced and confirmed by combining two or more techniques
of epitope mapping [20,21]. These results may be consolidated
by the T-cell ones, especially for the vaccine development against
cancer [22,23] or intracellular pathogens [24–26].2. The different methods for B-cell epitopes’ mapping
The following paragraph documents the different physical,
computational and binding methods used in B-cell epitope map-
ping for vaccines and diagnostics production.2.1. Crystallography-based methods
Co-crystallization of antigen–antibody complex is one of the
first techniques that were used in epitope mapping. In this tech-
nique, the highly purified antigens are obtained and allowed to
co-crystallize with their corresponding antibodies. Then, the
atomic structure of the complex is solved using X-ray diffraction
analysis. The structure of the epitope is obtained by solving the
three dimensional coordinates that represent the electron densities
of the amino acids of the antigen–antibody complex [1,10,27]. The
amino acids that are within a distance of 4 Å of each other are con-
sidered to be counteracting [6]. Unlike several techniques of B-cell
epitope mapping, the co-crystallization method is able to detect
continuous linear epitopes as well [4,10]. However, the technique
is obviously complex and expensive, as it requires large amounts
of highly purified protein-mAbs (monoclonal antibodies) com-
plexes and the structure of the mAbs should be known [1,28].
Obviously the antigen–antibody complex must be crystallizable
[29]. Thus some antigens are still mapped by this technique to
reveal the B-cell epitopes of malaria [30] and bilharzias [31]
parasites.
Thoughts to apply electron-microscopy (EM) to reveal the anti-
gen–antibody interaction were not practical, since the complex-
molecule was subjected to degeneration and dryness [32]. Since
the beginnings of 2013 the progress in cryo-EM analysis technique
re-introduced the use of EM to study the freezed antigen–antibody
complex in a non-crystalline amorphous thin layer, especially
when coupled with X-ray crystallography [33]. The new technique
requires less amount of complex, do not necessitate high purity of
the complex’s components, and the ability of the complex to crys-
talize is not a must [32]. This technique was recently used to map
the B-cell epitopes of HIV-1 [34] and HPV [35], or in combination
with X-ray crystallography to map poliovirus type-1 and 2
[36,37] and to study the structure of the rabbit hemorrhagic virus
[38] for vaccines’ production.
2.2. Mass spectrum-based methods
The application of mass spectrum (MS) in epitope mapping had
positively influenced the identification and characterization of dis-
continuous epitopes [39]. In general, there are two main methods
to use MS in epitope mapping. The limited proteolysis method, in
which different proteases are applied to the antigen of interest.
The fragments released from the different cleavage-sites in the
presence and absence of the antibody are detected by MS to reveal
the bound fragments to the antibody [40]. While in the epitope
excision method extensive proteolytic digestion is applied to the
antigen incubated with antibody coated beads. The beads are then
washed for several times to eliminate the non-epitope fragments
leaving the epitope fragments bound to the antibody. The epitopes
are then liberated by acid washing for further identification by LC-
MS or MALDI/MS [41,42]. One of the major limitations of this
method is the resolution which is, the ability to accurately deter-
mine a peptide fragment. The reason is that the limited proteolysis
and epitope excision approaches require proteolytic digestion with
trypsin. Therefore, epitope mapping is confined only to cleavage
sites which results in the identification of long peptides (typically
30–60 residues) that poorly define the epitopes. In addition, the
method is more concerned by the location of the reactive residues
on the antigen of interest rather than the spacing between them
[39], that shares in the conformational structure of the epitope.
The antigen–antibody complex placed in deuterated solvent,
will exchange the deuterium atoms with the free non-bound sites.
After digestion with pepsin the level of deuteration may be esti-
mated by MS [43]. Hydrogen–deuterium exchange method cou-
pled to MS (HD-MS) technique was used to overcome the defects
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between the antigen and antibody. The antigen can be used with
moderate purity, and polyclonal antibody may be applied [6].
However this method is still a rough mapping method, since it can-
not identify epitopes of less than 10–20 residues long. Although
the occasions when MALDI/MS was used to map the epitopes have
been quite limited, the approach was used in mapping the epitopes
of human thrombin [39], and HIV-1 gp41 [44]. Later on the HD-MS
method was used as well to study the epitopes of the antibody
against the coagulation factor to prevent Hemophilia symptoms
[45]. While more recently Temporini et al. [42] mapped the glyco-
proteins of tuberculosis using the LC-MS technique.2.3. Nuclear magnetic resonance (NMR)
When a high magnetic field is applied to a sample, the protons
associated with each amino acid absorb electromagnetic radiation.
The 3D-structure of the target protein could be constructed by
measuring distances and angles between amino acids residues.
NMR analysis provides a detailed structure analysis for epitope–
Fab (fragment antigen binding) interaction, therefore the nature
of epitope recognition could be accurately explained [1]. In this
technique, the protons of the Ag-Ab are subjected to the effects
of magnetic field and pulsed electromagnetic radiation in order
to obtain a dynamic picture of the protein complex in solution
and to construct the atomic definition of the Ag–Ab interface
[1,46,47]. However, this technique has some significant drawbacks
such as a high degree of sophistication, demand for technical
expertise, expensive instrumentation, and sometimes gives contra-
dicted results with X-ray results [1,19]. Furthermore, this tech-
nique is only applicable to continuous small molecular weight
proteins that are below 30 kDa [48]. Moreover, the structure of
the antigen should be known, Ag-Ab should be highly pure, and
present in relatively high concentration [6]. NMR was successful
in mapping the epitopes of MUC1, a breast cancer associated anti-
gen [49,50], and E7 protein of Human Papilloma Virus-16 (HPV)
[51]. Simultaneously, the technique was used to study of mecha-
nism of action and binding sites of heparin [52]. More recently,
NMR was used to identify the appropriate epitope of Tau protein
associated with Alzheimer to be used as diagnostic tools for the
disease [53]. In other cases, NMR was combined with surface plas-
mon resonance to identify the epitopes of Legionella pneumophila
[54].2.4. Surface plasmon resonance (SPR)
SPR is a complex physical technique that has wide variety of
applications, one of which is epitope mapping. SPR is a powerful
method for the analysis of low affinity-protein/protein interac-
tions. The physical principles of the technique is very complex,
however a suitable working knowledge of the technique does not
involve extensive theoretical background. The instruments are
appropriate for the evaluation of the binding of recombinant-
proteins to natural ligands and mAbs. SPR immunoassay resembles
the concept of the ELISA technique, but it is label free [55,56]. It
was first used in 2002 by Kooistra et al. [54] to map an important
outer polysaccharide that serves as an epitope for L. pneumophila
using NMR and SPR as discussed before.
However, SRP has shared practically in mapping the epitopes of
the active form of vitamin B12 (holo-transcobalamin) [57], the
manganese transport protein C (MntC) of Staphylococcus sp. [58],
the epitopes of Hemophilia disease [59], and ricin toxin [60]. In
other cases, SPR was combined with phage display technique for
epitope mapping to identify the major epitopes of Goodpasture
auto-immune disease [21]. It was combined as well with bindingand in silico techniques to identify the cross-reactivity between
the milk and soy bean allergens [61].
2.5. Computational-based methods
Computational docking is a computer-based method for epitope
mapping that depends on the generation of two distinct crystal 3D-
structures for the antigen and the antibody and subsequently cre-
ating a battery of computer algorithms in order to dock in silico one
structure onto the other. In 1982 Kuntz et al. created DOCK, which
was the first docking program [62]. Docking programs are assum-
ing that the structure of the antigen–antibody complex is repre-
senting the lowest free energy state accessible to the system
[63]. The major drawback in docking algorithms is the scoring
functions, since high scoring functions do not ensure achieving a
near native predicted complex [64,65]. However, this technique
is able to predict the small protein molecules complexes such as
enzyme-inhibitor/ligand complexes and antibody-hapten com-
plexes, since large molecules undergo many conformational
changes that makes docking procedure extremely difficult
[66,67]. In essence, little was focused on using this approach in epi-
tope mapping [66], however the method was used to map the
H1N1 epitopes [68], and was combined with mutagenesis method
to map HIV-1 [69].
Recently the in silico computer-based software used to predict
the possible Ag–Ab interactions greatly developed. Those new
bioinformatics products were used to screen protein epitopes of
several antigens in order to reduce further studies by molecular
methods, hence reduce cost, time and efforts. In silico products
are usually used to screen the epitopes of newly studied antigens
that have a defined genetic profile or those antigens of emerging
uncontrollable microbes [70]. Nowadays several B-cell epitopes
databases are available for many antigens [71–73]. Those include
the two protein–protein docking methods, DOT [74] and Patch-
Dock [75]. Together with the one-structure-based epitope predic-
tion tools such as CEP [76], DiscoTope [77], and ElliPro [78]. As
well as the two structure-based methods for protein–protein bind-
ing site prediction such as ProMate [79], COBEpro [80], BCpred
[81], BepiPred [82], BePpro [83], and Seppa [84]. Moreover, com-
mercial techniques such EpiquestTM 2014 software sold by APTUM
Biologics Ltd, and online web-based software such as Epitopia
[85], and B-pred [86] appeared. Simultaneously combinatorial
methods able to detect both T- and B-cell epitopes appeared such
as Jameson-Wolf DNAStar [87].
The technique was used to unravel the target epitopes of the
transforming growth factor (TGF)-b1 to control hepatic fibrosis
[88], Hemophilia control factors [89], Mycobacterium avium
(MAP) that correlates with diabetes disease in humans [90–94],
anthrax [95], the emerging nosocomial bacteria Acinetobacter
[96] and Klebsiella [97], HIV [98], Epstein–Barr virus (EBV) [99],
foot and mouth disease virus [100], Crimean–Congo hemorrhagic
virus [101], blue tongue virus [102], Chikungunya virus [103],
and to detect the allergens of soybean [104], eggplant [105], pea-
nut [106], and the under-researched onion [107]. Some studies
combined the in silico approaches with binding analysis to identify
the epitopes of snake venom [108], and soybeans cross-reactivity
with milk allergen [61].
2.6. Binding assays
Binding assays depend on the ability of an antibody to bind to
different fragments of an antigen that may be either a protein or
a polysaccharide. They have the advantage of being able to quan-
tify the immune response towards a specific epitope [1].
Western blot is a technique, used to screen individual epitopes
in a mixture, and may be applied to semi-quantify the relative
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electrophoresis in a carrier matrix (polyacrylamide gel) in order
to separate them according to size, charge, or other differences in
individual bands. Then, the separated bands are transferred to a
carrier-membrane (e.g. nitro-cellulose, nylon or PVDF), where they
are allowed to interact with antibodies specific to the target anti-
gen(s). The antigen could be detected with radio-active, or fluores-
cent labels, or enzymes that give a subsequent reaction with an
applied reagent, resulting in a coloring or emission of light
[109,110]. The western blot method is simple, reliable, and sensi-
tive. In addition, it is able to scan the whole epitopes of a pathogen
all at once, either being conformational or linear. It is used to
detect both macromolecules and hapten epitopes [111]. Also the
technique managed to map the epitopes of almost all antigens such
as bacteria [112], fungi [113], human diseases [114], and parasites
[115]. ELISA usually integrates with immunoblot to enable
the accurate quantification of a specific identified epitope
[1,109]. The techniques applied to perform ELISA in one-step
evolved [116].
However, the dot blot technique requires spotting of the puri-
fied bio-molecule to be detected directly on the membrane. In this
technique, there is no need to separate the macromolecules by
electrophoresis. Although used mainly for qualitative detection, it
might also be used as a semi-quantitative method [1]. Whereas,
the microarray methods are emerging as one of the major tech-
niques that are used in multiplexed detection of DNA [117,118],
proteins [119,120], peptides [121–124], antibodies [125], and car-
bohydrates [126], which are immobilized on planar supports such
as glass/coated slides [127]. Cells, as well as, tissues are examined
by microarrays that have wide spread applications such as plasmid
transfections, RNA interference, and serological assays [128–130].
The peptide microarrays (PMAs) is a promising tool that has a wide
variety of applications such as epitope-mapping, substrate profil-
ing, and probing peptide–ligand interactions [121,131]. SPOT syn-
thesis techniques developed for the profit of peptide microarray
assays [132–135]. Recently, the technique developed through a
next-generation application using a high-density peptide microar-
ray, that can perform thousands of tests at the same time [136]. In
general, the technique has several advantages such as high-
throughput, improved reproducibility, high-density and low sam-
ple consumption. However the technique has limitations including
the difficulty of getting highly purified peptides, and the orienta-
tion of the spotted proteins because of the limited number of the
reactive sites of a protein [137]. Moreover, PMAs are only capable
of detecting linear epitopes. Thus, PMA is an excellent method for
mapping protein binding sites that were solved before, and not for
discovering new interaction between proteins [138].
The applications of the binding techniques to screen the potent
epitopes are rich; however, the majority of applications were
directed towards western blot and ELISA. ELISA was a pioneer tool
in epitope mapping by binding procedures. It was used in mapping
the epitopes of HIV-1 envelop subunit vaccines, recombinant
gb120 and rgb160 [139,140], HCV [141], the Japanese Encephalitis
Virus (JEV) [142,143], hepatitis E virus (HEV) [144], EBV [145],
Klebsiella pneumoniae [146], gonococcal saccharides [147], Entero-
cytozoon bieneusi [148], gastrointestinal cancer [149], MAP similar-
ity with proinsulin [150], and plectin (a major component of the
cytoskeleton) [151,152]. Western blot/ELISA combinatorial system
was successful in mapping the uropathogenic Escherichia coli [153],
Staphylococcal a-hemolysin [154], and Brucella melitensis periplas-
mic protein [155]. The combinatorial methods were used by sev-
eral researchers since 1989 to map the epitopes of the emerging
nosocomial pathogen K. pneumoniae [156]. Sample specifications
and screened antigens varied among trials [157–160], till a potent
epitope-based vaccine and diagnostic against the pathogen was
patented [161].Furthermore, western blot/ELISA techniques were also used in
mapping several viral epitopes such as the epitopes of hepatitis B
virus (HBV) [162], JEV [163], Dengue fever virus [164,165], Cyto-
megalovirus (CMV) [166], bovine leukemia virus glycoprotein
[167], and Beet Necrotic Yellow Vein virus [168–170]. Moreover,
western blot was practiced in mapping the epitopes of the human
sperm [171,172], systemic lupus erythematosus (SLE) [114], and
allergens [173,174]. Epitopes of the parasites such as malaria
[175], and Treponema pallidium [176] were also mapped by the
same technique.
Simultaneously several diagnostic tools were identified using
immunoblot/EILSA techniques such as the MAP antigens in dia-
betic patients [177–179], Parkinson disease [180], and Leishma-
nia’s parasite [181].
PMAs appeared as a useful tool for epitope mapping of Rubella
Virus, CMV, Toxoplasma gondii, and Herpes Simplex Virus type I and
II [182,183], protein MPB70 of Mycobacterium bovis [184,185],
bovine leukemia virus [186], polymorphic protein of Plasmodium
falciparum [187,188], murine and human anti-hTSHR antibodies
[189], Lupus auto-antibodies [190], bovine b-lactoglobulin [191],
Atlantic code in Spanish people [192], brain cancer diagnostics
[193], and Potato Y virus diagnostics [194]. Trypanosoma cruzi epi-
topes were re-studies by high density peptide microarray in order
to develop a vaccine and a diagnostic tool against the parasite
[195,196]. ELISA was combined with PMAs to screen the epitopes
of foot and mouth disease virus [197], HEV [198–200], the Tau pro-
tein in Alzheimer’s disease [201]. Western blot was combined with
ELISA to map the epitopes of Pneumocystis carinii [113], and the
main antigenic protein in Bullous pemphigoid [202].
Binding methods proved to be successful for epitope mapping
when combined with pepscan as in the mapping of the epitopes
rotavirus-A [203], the recombinant adeno-associated virus type 2
[204], the outer membrane proteins of Chlamydia pneumoniae
[205], and Bacillus anthracis [206]. The application of binding meth-
odswas sometimes combinedwith themutagenesis technique as in
the identification of several potent protein epitopes of Plasmodium
malaria [115], and the staphylococcal enterotoxin B [112]. Addi-
tionally, a combination of several methods of epitope mapping,
specifically western blot, ELISA, and phage display highlighted a
potent epitope of Mycoplasma hyopneumoniae [20]. Moreover, in
2012Maksimov et al. [207] demonstrated the potential of eight epi-
topes of T. gondii using PMA and a bioinformatics–based approach.
The immunoblot/ELISA was used sometimes in combination with
SPR and in silico techniques to detect the common epitopes
between the soybean and milk [61], or the phage display to study
the mycobacterial complicated protein epitopes [208].
2.7. Mutagenesis
Mutagenesis is a vital technique whereby DNA mutations are
deliberately engineered to produce mutant proteins. The mutant
protein (antigen) can be examined to determine the effect of the
mutation on its ability to bind to a target antibody and determine
the genuine epitope of that antigen [1,209–213]. The method is
popular as it is relatively simple [211], however results obtained
from the technique might be confusing because the mutated con-
tact amino acids can either stimulate binding, inhibit binding, or
show no effect [1]. Mutagenesis could be classified according to
the technique used to induce the mutation into three main cate-
gories the site directed mutagenesis, the shotgun mutagenesis,
and the site directed masking [110].
Site directed mutagenesis is one of the simplest methods of epi-
tope mapping [211], in which a highly specified mutation is intro-
duced into a specific sequence of the antigen of interest and then
the antigen is tested for its ability to bind to the corresponding
antibody. Failure of binding signifies that a particular amino acid
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fore constructing a map for the epitope of the antigen being tested.
Site directed mutagenesis could be classified as either alanine
scanning mutagenesis (ASM) or saturating mutagenesis [1]. In
ASM, every single residue in a specific peptide sequence is subse-
quently replaced by alanine one at a time and at the same time,
and glycine usually replace alanine residues that are present in
the original sequence [209,210]. Therefore, the central amino acids
in the studied antigens that are necessary for antigen–antibody
recognition can be identified. However, this technique has some
significant drawbacks since the method involves great exertion
due to the necessity of producing many mutants, purifying them,
and evaluating their structural integrity and binding capacity. Fur-
thermore, the results obtained by ASM are not usually matched
with the physical binding site identified by crystallographic meth-
ods [1]. On the other hand, saturating mutagenesis depends mainly
on inducing random mutations in the DNA sequences [214,215] by
using several chemical reagents such as nitrous acid [216] and
hydroxylamine [217]. Other chemical reagents such as formic acid
[218,219] and hydrazine [220] have the ability to damage the bases
of DNA causing incorrect base pairing [214]. In this technique, a
low fidelity DNA polymerase is used in order to create random
mutations in the amplicon (the product to be amplified) in PCR
amplification [221]. In essence, site directed mutagenesis is a con-
fusing tool for epitope mapping due to the fact that many muta-
tions that have significant effect on the degree of binding
between the target being tested and the monoclonal antibody
could be misleading as they are not part of the real epitopes [1].
Shotgun mutagenesis uses a high throughput technology for the
identification of the binding sites between antigens and their cor-
responding antibodies. This technique enables the expression and
analysis of large libraries of mutated target proteins by introducing
systemic mutations that nearly cover all the amino acids in the tar-
get protein in order to determine the amino acids that play an
essential role in the binding process. Using a high throughput
‘‘Shotgun Mutagenesis” approach for epitope mapping, one can
rapidly construct comprehensive epitope maps across the entire
sequence of difficult target proteins such as G protein-coupled
receptors [212].
A more recent methodology to map epitopes by mutagenesis,
called site directed masking, was introduced by Paus and Winter
in 2006. The technique is only applicable when the 3D-structure
of the protein is available [213]. In this approach, the protein anti-
gen surface is occupied by a panel of single cysteine mutations that
is used, along with a linker to solid phase, to block accessing of
antibody to this location [222]. Therefore, the mutations which
prevent antibody binding specify the location of the antibody epi-
tope interaction, which can be further enhanced by alanine scan-
ning mutagenesis [222].
Mutagenesis techniques had shared practically in the mapping
of the epitopes of the hen egg-white lysozyme allergen [223], the
house-dust-mite allergen [224], HIV-1gp120 [225], the E2 envel-
ope protein of hepatitis C virus (HCV) [226], Foot and mouth dis-
ease virus [227], Dengue’s virus [228], and Plasmodium’s parasite
[229]. Occasionally, site directed mutagenesis technique was
shown to be successful when combined with the phage display
method of epitope mapping. This was shown in the mapping of
the epitopes of the human plasminogen activator inhibitor-1
[230], and the alpha subunit of the nicotinic acetylcholine receptor
[231]. While, the mutagenesis approach was combined with pep-
scan in the mapping of the human CD20 monoclonal antibodies
with potent cytolytic activity against non-Hodgkin lymphomas
[232]. The application of mutagenesis techniques of epitope map-
ping was combined sometimes with other binding methods
[112,115] or with SRP [21] as previously discussed and phage dis-
play [233,234]. High-throughput mutagenesis was usually pairedwith next generation in silico sequencing. A genome wide library
of HCV and mutagenesis succeeded to map the epitopes of HCV
[235], as well as different antibodies targeting Pertussis Toxin,
TNF, and the cancer target TROP2 [236].
2.8. Pepscan
In 1984, Mario Geysen launched a new method for epitope
mapping, in which the desired antibody is investigated against a
library of peptide sequences from the protein of interest (antigen)
to test their ability to bind to the desired antibody [110,237]. The
segments of peptides that have the ability to bind to the antibody
of interest demonstrate a significant part of the antigen [226]. The
presence of two distant peptides that share the ability to bind to an
antibody of interest due to having structural similarity signifies
that these two peptides are contributing to the intact epitope of
interest [1].
Geysen and coworkers’ technique is very suitable for the in vitro
identification and characterization of T-cell epitopes, as well as B-
cell epitopes [237,238]. B-cell epitope analysis procedure by pep-
scan involves four major steps, which are the chemical synthesis
of peptides immobilized on polypropylene pins, then the use of
ELISA as a method for binding analysis, followed by
bioinformatics-based data analysis, and finally constructing initial
results [127].
In general, there are two types of the chemical peptide synthe-
sis, solid phase peptide synthesis and multiple synthesis on pins. In
the solid phase technique, peptides are constructed on an insoluble
polymeric support by sequentially adding amino acids. In multiple
synthesis on pins technique, amino acids are synthesized on pins
that are fixed to a plastic support and then incubated with antibod-
ies of interest [127,239,240]. Binding analysis methods such as
ELISA are often used for the evaluation of the binding capacity of
the synthesized peptides with the antibodies being tested
[127,239,241].
Usually, there is confusion between the two terms pepscan and
peptide microarrays (PMAs). In general, the use of the term to refer
to a pepscan implies the use of a binding analysis technique such
as ELISA to confirm the binding capacity of a desired antigen/anti-
body towards different synthetic peptides, while the PMAs is just a
collection of different peptides displayed on solid surface such as
plastic or glass chip [123,242]. In some experiments, the pepscan
approach was combined with the peptide microarray technique
in order to achieve better results [122,243,244].
The advancement in the field of bioinformatics assisted the
development of peptide microarrays techniques. The pepitope ser-
ver is a very promising bioinformatics tool used in the prediction of
discontinuous epitopes based on affinity-selected peptides. It is
composed of three algorithms for epitope mapping: PepSurf, Mapi-
tope, and a combination of the two in order to run and compare
between two epitopes that use different methodological
approaches through a single web platform [245–248].
In general, the method has a wide variety of applications, rang-
ing from the identification of epitopes present on monoclonal anti-
bodies [249] to the screening and detection of epitopes present on
bacteria [250–252], viruses [253,254], parasites [255,256], tumor
markers [257–259], and enzymes [260]. Moreover, the technique
has been extensively used in the design of vaccines [261–263].
However, the technique is limited to the identification of linear
epitopes [1,264] and requires a confirmatory binding method
[122]. The method proved to be successful when combined with
the phage display method. In 2001, Yip et al. [265] identified the
several epitopes of ErbB-2, a self onco-protein that is highly
expressed in several types of cancer. Furthermore, as discussed
before, pepscan can combine with mutagenesis approach [232],
and binding methods [203,204,266].
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One of the most powerful techniques is based on testing the
binding capacity of a variety of peptides displayed on the surface
of a bacteriophage to the monoclonal antibody of interest. In
1985, Smith and Petrenko managed to express a variety of peptide
sequences on the surface of non-lytic filamentous bacteriophage
[267,268]. In this technique, when a foreign DNA was inserted into
the genome of M13 filamentous bacteriophage, viral peptides
including the foreign DNA were synthesized and displayed on the
amino terminal portion of the viral coat protein. Smith stated that
phage particles are representing a link between the genotype i.e.,
encapsulated nucleic acid) and the phenotype (i.e., expressed cap-
sid proteins) [269,270]. Furthermore, in 1990, McCafferty et al.
[271] showed that an antibody fragment could be displayed on
the phage surface, and even a hormone could be displayed on
the surface of the bacteriophage [272]. The creation of vast arrays
of slightly different viral peptides is accomplished by allowing each
position in the viral vector oligonucleotide to acquire any of the
four possible nucleic bases. As a result, nucleic bases randomiza-
tion allows the creation of all possible combinations to be pro-
duced. Each phage is capable of producing unique peptides that
correspond to the specified code in its genome [1,273]. Recently,
automated phage display software appeared [274]. Nevertheless,
several surface display systems were recently developed using
yeast and bacteria [275–278], and cell-free display systems such
as mRNA display [279] and ribosome display [280,281].
There are four main steps that are critical for the selection of a
specific phage peptide from a phage display library. First, capturing
of binding phage on immobilized antigen from the library of pro-
teins displayed on the phage surface using ELISA. Second, washing
to remove unbound particles. Third, elution of the bound phage.
Fourth, sequencing the target peptide and amplifying the gene cod-
ing for it in a suitable host organism such as E. coli [282].
Although, the technique is very powerful in mapping the main
epitopes of viruses, bacteria, and cancer antigens, it is sophisticated
and needs high expertise. The technique seems to be more suitable
for the screening of the epitopes of viruses and cancer antigens due
to the extreme need for the precise identification of target epitopes
[1]. Moreover, it requires the use of a binding analyses technique
such as ELISA.
The technique was applied on several occasions to screen the
epitopes of the intrinsic membrane protein neutrophil cytochrome
b [283], rituximab, a chimeric monoclonal antibody against the
protein CD20, which is found on the surface of B-cells [284], buf-
falo b-lactoglobulin allergen [285], and EBV [286]. Yeast surface
display was applied to map the hemagglutinin of H5N1 influenza
virus [287], while it was used more recently to map the HIV-
gp120 epitopes [288]. As discussed before, surface display tech-
nique was combined with several mapping techniques [20,21,208
,230,231,233,236,265,289] to resolve the epitopes of different
antigens.3. Comment
The first approaches to produce immunotherapies and diagnos-
tics depended on the use of the whole antigens. However, the
advancement in immunology proved that the pre-production
design of those preparations has an apparent clear positive impact
on the potency, specificity, and safety. The ability to detect the
pure immunogen that interacts specifically with the first, obvious,
and selective immune signal has a great interest in the design of
diagnostics. However, the possibility of identifying the safe anti-
genic determinant, which triggers the humoral immune response
against a specific antigen, ensures the design of a potent vaccine.Collectively, the detection of those responses is performed by the
B-cell epitope mapping techniques.
The B-cell epitope mapping has undergone a series of evolution
and development steps. The physical methods for epitope mapping
preceded the binding ones. Although X-ray was applied almost a
century ago, it was complex and ineffective in identifying B-cell
conformational epitopes. Therefore, MS developed to characterize
discontinuous epitopes after being randomly fragmented. Later
on, MALDI/MS was followed by the expensive NMR technique that
requires high degree of expertise and sophistication, and only can
resolve small continuous low molecular weight proteins. However,
cry-electron microscopy and HD-MS techniques reintroduced the
use of those techniques to an extent. These techniques were fol-
lowed by docking computational method that depends on the pre-
diction of the lowest affinity energy between lowmolecular weight
3D-protein structures, while the most recent physical technique
was the SPR that has some applications for epitope mapping in
the last decade. In general, physical techniques were not ideal ones
for epitope mapping, unless coupled with pepscan or phage display
methods. Even though the advances in in silico computational
methods were effective in predicting the possible antigenic deter-
minants, they requested a confirmation step by molecular
techniques.
In a parallel line, the use of the first binding technique, ELISA
arose by the 1960’s, and developed rapidly to mutagenesis, west-
ern blot, dot blot and microarray that synchronized the same time
of using SPR. Although PMA and dot blot have high throughput,
high reproducibility, low sample consumption, together with the
necessity to purify the epitopes limited their use against the west-
ern blot. Moreover, dot blot and PMA can only detect linear epi-
topes, and hence cannot be used alone to investigate new
epitopes. During the mid-1980’s pepscan and surface display
methods appeared for epitope mapping. Those latter two methods
depend on binding and bioinformatics approaches. Later on the in
silico software evolved to scan the genetically mapped antigens. It
is apparent that all techniques possess advantages and defects
(Table 1). Therefore, their use depends on the case to be studied
and the type of available data if any. For the same reason, combi-
natorial methods appeared to reduce time, expenses, and to give
better results.
Although the majority of B-cell epitopes are non-linear discon-
tinuous folded amino acid sequences, some may be polysaccharide
(PS) molecules. NMR, SPR, ELISA, PMA, dot blot and western blot
techniques have the advantage of detecting polysaccharide epi-
topes, hence they were used to detect the PS of Legionella, Shigella,
Klebsiella, and breast cancer cells. However, western blot owned
the over-privilege for the first step of screening mixtures or whole
antigens with no need for purification like in all other techniques.
Therefore, this method was used to screen unknown epitopes in
mixtures. Although in silico software were used to screen new
unknown eptiopes, a complete genetic map for the antigen was
necessary to apply the method. All reported molecular mapping
methods are mainly able to detect epitopes qualitatively; however
the ELISA, dot blot, and western blot methods are able to make
quantitative analysis. Despite mutagenesis, surface display, cryo-
EM and ELISA were able to detect the discontinuous conforma-
tional epitopes; the X-ray, NMR, pepscan, dot blot and PMA were
restricted to continuous linear ones, whereas the MS-dependent
methods and western blot were able to determine both types of
epitopes (Table 1).
The systematic review of the B-cell epitope mapping used to
map different antigens, highlighted the correlation between speci-
fic methods and certain antigens. Pepscan and the different binding
methods showed a remarkable superiority for epitope mapping of
diagnostics for bacteria, viruses, tumor markers, and Candida sp.
(Table 1). The epitope mapping for vaccines depended on the same
Table 1
Comparison between the different methods used for B-cell epitope mapping.
X-ray/cryo-
EM
MS-based NMR SPR In silico ELISA Western Dot blot PMA Mutag-
enesis
Pepscan Surface
display
Epitope Type Pr. Gl/Pr. PS/Pr. PS/Pr. Pr. PS/Pr. PS/Pr. PS/Pr. PS/Pr. Pr. Pr. Pr.
Purity High Mod High High – High mixture High High High High –
Concentration High High High High – Small Small Small Small
Structure Known Known Known Known Known Depends* Unknown Known Known Known Known Known
Genetically
mapped
No No No No Yes No No No No Yes Yes Yes
Size Variable Variable Small
(660 kDa)
Variable Mod. Variable Variable Mod. Mod. Mod. Mod. Mod.
Conformation Linear/Conf Linear/Conf Linear Conf Linear/Conf Linear/Conf Linear/Conf Linear Linear Conf Linear Conf
Quantification No No No Weak No Yes Semi Semi Semi No No No
Ab mAb
structure
Known PL Known No Known Depends* PL PL PL Pure Pure Pure
Application Number of
samples
Lim. Lim. Lim. Lim. Large Mod. Mod. Large Large Mod. Mod. Lim.
Combination X-ray/cryo-
EM
– SPR NMR/SD/PC MT/WT/
PMA
PC/WT PC/PP/EL – EL/WT/PC/SD CS/PP/SPR/
PC/WT
MT/PMA/SD SPR/PMA/
MT/PP
Sophistication Yes Yes Yes Mod. Mod. Simple Simple Mod. Mod. Mod. Mod. Yes
Defects Expensive &
complex
Rough
(P20 kDa)
Expensive&
expertise
Expensive Predictive – – Linear
epitopes
Linear epitopes Confusing
results
Requires
peptide library
Complex
Previous uses Pa & Vs Bt; Ds. & Vs Cs; Ds; Bt &
Vs
Al; Bt; Ds;
Tx & Vt
Al; Bt; Ds;
Tx &Vs;
Bt; Cs; Ds; Pa;
Vs & Dg
Al; Bt; Fg; Ds;
Pa & Dg
Ba & Dg Bt; Cs; Ds; Pa;
Vs & Dg
Al; Cs; Ds.
& Pa
Bt; Cs; Ds; Pa;
Vs & Dg
Al; Ba; Cs
& Vs
Key: Al = Allergens; Bt = Bacteria; Conf = Conformational; Cs = Cancer; Dg = Diagnostics (antibodies); Ds = Disease; EL = ELISA; Fg = Fungi; Gl = Glycoprotein; PC = in silico; Lim = Limited; Mod = Moderate; MT = Mutagenesis;
Pa = Parasite; PL = Polyclonal; PP = Pepscan; Pr. = Protein; PS = polysaccharide; SD = Surface display; Tx = Toxins; Vt = vitamins; Vs = Virus; WT =Western.
* The structure of the Antibody or epitope should be known in case of ELISA.
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sis procedures. The mixed bacterial epitopes were mostly screened
by western blot, and surface display. While those of the viruses
depended mostly on microarray and/or pepscan, ELISA or phage
display. Those of parasites were detected by ELISA and sometimes
mutagenesis, however tumor markers were usually investigated by
phage display, pepscan and mutagenesis, Pneumocytes carnii was
mapped by ELISA with western blot. Finally, allergen and autoim-
mune diseases were revealed by mutagenesis and western blot.
Several combinations appeared where the pepscan was a basic
technique together with binding methods, especially for viruses, or
mutagenesis for cancer epitopes mapping; fewer methods
appeared for mutagenesis with binding methods for cancer epi-
topes. Epitope’s mapping revealed the major epitopes that may
be used as vaccine and diagnostic building blocks for several tumor
antigenic determinants such as PSA, CD-20 (rituximab), breast can-
cer, and pancreatic cancer. Screening of theMycoplasmsa bovis epi-
topes by pepscan and PMA was fruitful. Moreover, several
successful studies on K. pneumoniae using western blot technique
highlighted the major precise blocks for vaccine and diagnostic
production.
The primary screening of emerging pathogens were usually per-
formed by western blot and pepscan, as well as, in silico software if
the genetic material of the antigen was provided. Mapping showed
a major role in screening the epitopes of the Rotavirus by pepscan
and PMA; SARS by PMA, pepscan and ELISA; HCV by ELISA and
mutagenesis; and HIV-1 gp41, gp120 and gp160 by pepscan, ELISA
and western blot. It is obvious that the combinations of at least two
methods ameliorate the results and refine them remarkably.
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